RxDoctor Payments Data

Michael Curi, MD

Vascular Surgery · Newark, NJNPI 1033222161

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,725 of the $32,311 with a category attached, or 70.3%. Humacyte Global, Inc. accounts for 70.2% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $24,268, more than ten times the $896 reported in 2019. Among vascular surgery clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,311in general payments, 2019–2025

Across 98 payments — averaging $329.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Humacyte Global, Inc.$23K
  • Advanced Oxygen Therapy Inc.$3K
  • Cook Medical LLC$2K
  • W. L. Gore & Associates, Inc.$1K
  • Silk Road Medical, Inc.$892
  • Medtronic$755
  • plus $2K from 16 others
$11,063in research payments, 2019–2025

Across 4 payments — averaging $2765.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Humacyte Global, Inc.$11K

What the payments were for

  • Consulting fees$22,72570%
  • Grants$6642%
  • Travel & lodging$3,24210%
  • Food & beverage$5,68018%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,311 in reported general payments places this provider in the 90th percentile of 182 vascular surgery providers in New Jersey.

See all vascular surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$50,896
Medicare patients
204
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$10,812
ClopidogrelClopidogrel Bisulfate22$191

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →